Pfenex (PFNX) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
- Sysco calls on Teamsters to end LA strike after economic deal reached
Pfenex Reports First Quarter 2018 Results and Provides Business Update
May 10, 2018 4:02 PM EDTSAN DIEGO, May 10, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfnex Expression Technology® to improve protein therapies for unmet patient needs, today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
... More


